MBrace Therapeutics
MBrace is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment through innovative antibody-drug conjugates (ADCs). They focus on discovering new cancer targets and developing targeted therapies, including their lead ADC product MBRC-101, which is currently in clinical trials. Their mission is to provide new therapeutic options for cancer patients by translating innovative ADC discovery into transformative therapies.
Industries
Nr. of Employees
small (1-50)
MBrace Therapeutics
Products
Investigational ADC targeting EphA5 (lead candidate)
An investigational antibody‑drug conjugate that targets the EphA5 receptor tyrosine kinase; characterized by selective binding, rapid internalization, in vitro cytotoxicity against EphA5-expressing cells, and dose‑dependent anti-tumor activity in PDX models; currently in first-in-human Phase 1/1b dose‑finding and expansion studies.
ADC program in IND‑enabling studies (secondary pipeline program)
An ADC development program targeting a novel tumor antigen that is in IND‑enabling studies to support potential clinical entry.
Additional ADC discovery programs (preclinical pipeline)
Early-stage ADC programs targeting novel antigens discovered via in vivo selection; some programs are at discovery or preclinical stages with details forthcoming.
Investigational ADC targeting EphA5 (lead candidate)
An investigational antibody‑drug conjugate that targets the EphA5 receptor tyrosine kinase; characterized by selective binding, rapid internalization, in vitro cytotoxicity against EphA5-expressing cells, and dose‑dependent anti-tumor activity in PDX models; currently in first-in-human Phase 1/1b dose‑finding and expansion studies.
ADC program in IND‑enabling studies (secondary pipeline program)
An ADC development program targeting a novel tumor antigen that is in IND‑enabling studies to support potential clinical entry.
Additional ADC discovery programs (preclinical pipeline)
Early-stage ADC programs targeting novel antigens discovered via in vivo selection; some programs are at discovery or preclinical stages with details forthcoming.
Services
Identification of antibody–target pairs using in vivo selection approaches that prioritize tumor localization, selective binding, internalization, and stability to generate candidates for ADC development.
Partnerships and sponsored research with academic institutions and industry partners to in-license discovery assets and advance ADC programs through preclinical and IND-enabling stages.
Identification of antibody–target pairs using in vivo selection approaches that prioritize tumor localization, selective binding, internalization, and stability to generate candidates for ADC development.
Partnerships and sponsored research with academic institutions and industry partners to in-license discovery assets and advance ADC programs through preclinical and IND-enabling stages.
Expertise Areas
- Antibody-drug conjugate discovery and development
- In vivo antibody selection and target discovery
- Preclinical oncology models and PDX studies
- Early-phase clinical trial design and operations (Phase 1/1b)
Key Technologies
- In vivo antibody screening/selection
- Antibody-drug conjugation chemistry
- Patient-derived xenograft (PDX) models
- Bioassays and protein analytical chemistry
News & Updates
Presentation of preclinical data supporting the development of MBRC-101, an ADC targeting EphA5, at AACR 2024.
Announcement of the presentation of a trial in progress poster at ASCO 2024 for MBRC-101, an ADC targeting EphA5.
MBrace announced an $85 million Series B financing round to support clinical development of its ADC pipeline, including MBRC-101.
MBrace was shortlisted for 'Best New Drug Developer' and awarded 'Most Promising Clinical Candidate for MBRC-101' at the 11th Annual World ADC Awards.
Presentation of preclinical data supporting the development of MBRC-101, an ADC targeting EphA5, at AACR 2024.
Announcement of the presentation of a trial in progress poster at ASCO 2024 for MBRC-101, an ADC targeting EphA5.
MBrace announced an $85 million Series B financing round to support clinical development of its ADC pipeline, including MBRC-101.
MBrace was shortlisted for 'Best New Drug Developer' and awarded 'Most Promising Clinical Candidate for MBRC-101' at the 11th Annual World ADC Awards.